CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Clinical Trial of Anti-PD-1 mAb Therapy Alone or With Metabolic Modulators to Reverse Tumor Hypoxia and Immune Dysfunction in Solid Tumor Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04114136
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:29:02.996607+00:00
Published At: 2026-04-24T00:00:00+00:00
Record Updated At: 2026-04-24
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Melanoma", "NSCLC", "Hepatocellular Carcinoma", "Urothelial Cancer", "Gastric Adenocarcinoma", "HNSCC", "Esophageal Adenocarcinoma", "Microsatellite Instability-High Solid Malignant Tumor"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-04-24"
protocolSection.identificationModule.nctId: "NCT04114136"
protocolSection.identificationModule.officialTitle: "A Phase II Clinical Trial of Anti-PD-1 mAb Therapy Alone or With Metabolic Modulators to Reverse Tumor Hypoxia and Immune Dysfunction in Solid Tumor Malignancies"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.